Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02649686
Title Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: adult
Covered Countries CAN

Facility Status City State Zip Country Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
University Health Network Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field